All the news Showing 10 of 40 articles from: EASL 2016Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Hepatocellular carcinoma (HCC) People treated for hepatitis C have unexpectedly high rate of liver cancer recurrence Liz Highleyman / 28 April 2016 Hepatitis C patients with cirrhosis who were treated with direct-acting antivirals had about twice the expected likelihood of developing hepatocellular carcinoma (HCC), with the excess risk seen in people with a previous history ... Previous non-responders & relapsers Investigational combination ABT-493 and ABT-530 works well in patients who did not achieve SVR12 with previous DAA therapy Michael Carter / 26 April 2016 An experimental combination of direct acting antivirals (DAAs) is effective and safe in HCV-genotype-1-infected patients who did not respond to previous DAA therapy, according to research presented to the recent International Liver Congress ... Therapies Portugal's roll-out of HCV therapy with DAAs achieves impressive outcomes Michael Carter / 25 April 2016 Roll-out of hepatitis C virus (HCV) therapy using direct-acting antivirals (DAAs) has achieved excellent outcomes in Portugal, data presented to the International Liver Congress in Barcelona shows. Overall, 96% of patients had a ... Interferon-free regimens Adolescents with hepatitis C achieve high cure rates with sofosbuvir/ledipasvir Liz Highleyman / 25 April 2016 Sofosbuvir/ledipasvir (Harvoni) was well tolerated and led to sustained virological response in 97% of adolescents (age 12-17) with chronic hepatitis C, with high cure rates regardless of prior treatment experience or presence ... Therapies DAAs achieve excellent outcomes in real-world settings Michael Carter / 21 April 2016 Hepatitis C virus (HCV) therapy with direct-acting antivirals (DAAs) is as effective in real-world settings as it was in clinical trials, according to US research presented to the International Liver Congress in Barcelona ... Pan-genotypic regimens AbbVie pan-genotypic combination for hepatitis C achieves 97-100% cure rate in genotype 3 Keith Alcorn / 20 April 2016 A new combination of direct-acting antivirals developed by AbbVie is highly effective in curing hepatitis C in people with genotype 3 infection and cirrhosis, results of two phase II studies presented at last ... Interferon-free regimens Novel therapy RG-101 plus antivirals could cure hepatitis C in 4 weeks Liz Highleyman / 20 April 2016 Two injections of RG-101, an experimental drug that targets the micro-RNA miR-122 in liver cells, combined with direct-acting antiviral agents (DAAs) taken for just 4 weeks, led to 12-week post-treatment sustained response in ... Access to medicines & diagnostics How generic direct-acting antivirals are changing the landscape for hepatitis C treatment Keith Alcorn / 19 April 2016 The arrival of generic versions of direct-acting antivirals is transforming the global hepatitis C treatment landscape and highlighting the overlooked importance of the cost of monitoring technologies, delegates at the 2016 International Liver ... Treatment for people living with HIV and HCV Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection Liz Highleyman / 19 April 2016 A dual regimen of sofosbuvir plus velpatasvir was well tolerated and highly effective against hepatitis C virus (HCV) genotypes 1 through 4 in HIV-positive people with chronic hepatitis C co-infection, according to results ... Sexual transmission High incidence of HCV reinfection among HIV-positive MSM in Western Europe Michael Carter / 19 April 2016 There is a very high incidence of hepatitis C virus (HCV) reinfection among HIV-positive men who have sex with men (MSM) in western Europe, according to research presented to the International Liver Congress ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive